165 related articles for article (PubMed ID: 15234233)
1. Are multiple markers the future of prostate cancer diagnostics?
Mikolajczyk SD; Song Y; Wong JR; Matson RS; Rittenhouse HG
Clin Biochem; 2004 Jul; 37(7):519-28. PubMed ID: 15234233
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
3. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
4. Serum markers for prostate cancer: a rational approach to the literature.
Steuber T; O'Brien MF; Lilja H
Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
6. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
[TBL] [Abstract][Full Text] [Related]
7. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
8. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN
Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029
[TBL] [Abstract][Full Text] [Related]
10. [Prostatic specific antigen: role and significance in urologic practice].
Manolović D; Pejcić T; Milović N
Srp Arh Celok Lek; 1994; 122(5-6):171-3. PubMed ID: 17977420
[TBL] [Abstract][Full Text] [Related]
11. [Tumor markers of urinary tract carcinoma].
Kikuchi H
Rinsho Byori; 2004 Apr; 52(4):371-80. PubMed ID: 15164607
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
13. [PSA kinetics after total prostatectomy].
Riedinger JM; Eche N; Fulla Y; Thuillier F
Ann Biol Clin (Paris); 2009; 67(1):39-46. PubMed ID: 19189884
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen: an updated review.
So A; Goldenberg L; Gleave ME
Can J Urol; 2003 Dec; 10(6):2040-50. PubMed ID: 14704108
[TBL] [Abstract][Full Text] [Related]
15. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
17. Bloodborne biomolecular markers in prostate cancer development and progression.
Bok RA; Small EJ
Nat Rev Cancer; 2002 Dec; 2(12):918-26. PubMed ID: 12459730
[TBL] [Abstract][Full Text] [Related]
18. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project.
van Gils MP; Stenman UH; Schalken JA; Schröder FH; Luider TM; Lilja H; Bjartell A; Hamdy FC; Pettersson KS; Bischoff R; Takalo H; Nilsson O; Mulders PF; Bangma CH
Eur Urol; 2005 Dec; 48(6):1031-41. PubMed ID: 16054748
[TBL] [Abstract][Full Text] [Related]
19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
20. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]